Hospital

Olaparib (Lynparza) approved for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

Ryanodex is a skeletal muscle relaxant indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures.

Finch was still able to continue dosing patients in its past-ongoing PRISM-EXT phase 2 open-label trial of CP101 in recurrent CDI, because the CP101 lots used for PRISM-EXT were manufactured from material donated prior to December 1, 2019.

Michael Abrams, MPH, PhD, senior health researcher at Public Citizen’s Health Research Group, discusses whether classification of gabapentin as schedule V would end patients’ access to the drug.

In the third part of the series, we further explore the factors that contribute to overall happiness in a position.

Tapping their specific skill sets and training can help serve patients more effectively, although challenges exist.

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the growing shift to biosimilars in oncology and the impact of increased access and reduced financial burden for patients on medication adherence.

Study highlights the impressive efficacy of direct-acting antivirals, which have cure rates in the range of 98% in patients with hepatitis C.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses what oncology pharmacists should understand about rucaparib when treating ovarian cancer.

Last month, the FDA approved empagliflozin (Jardiance) to lower the risk of cardiovascular death and hospitalization for heart failure in adult patients.

Supplemental new drug application submitted to the FDA for the approval of darolutamide (Nubeqa) plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

The COVID-19 pandemic highlighted the importance of managing infections properly globally and the need for stewardship networks among partners.

Despite early excitement about the potential for pharmacists to prescribe COVID-19 oral antivirals, the program does not provide that ability.

The risk of death from CVD was approximately 15% lower for those with the highest vegetable intake compared to the lowest vegetable intake.

Investigators advise third short for patients with weakened immune system, especially organ transplant recipients.

Phase 3 TROPiCS-02 study continues to follow patients for overall survival, a key secondary endpoint.

Ten quiz questions to assess your knowledge on common treatments for heart failure.

Epcoritamab is an investigational immunoglobulin G1-bispecific antibody being evaluated as a treatment for patients with follicular lymphoma in multiple clinical trials.

Pharmacy Times will be covering the upcoming Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer live in Phoenix, Arizona, taking place March 18 through 21.

Enhanced tools in the field of structural biology may reveal new insights into HIV that could lead to a vaccine to protect against the virus progessing to AIDS.

Important evidence about the health effects of e-cigarettes can help shape public health best practices in the United States, the findings of an analysis suggest.

This will increase Moderna’s vaccine catalog to 5, including vaccines against cytomegalovirus (CMV), Epstein-Barr virus (EBV), and HIV, in addition to the immunizations for HSV, and VZV.

Poziotinib demonstrates positive results for treatment-naïve patients with non-small cell lung cancer harboring HER2 exon 20 insertion mutations.

Ivosidenib in combination with azacitidine found to significantly improve event-free survival in patients with previously untreated IDH1-mutated acute myeloid leukemia.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the adverse events patients with ovarian cancer have reported during treatment with rucaparib.

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses how oncology pharmacy professionals can effectively address fatalistic beliefs and perceptions of cancer-related information among rural adults.

Novel C. difficile infection (CDI) vaccine shows promise lowering the severity of CDI and in preventing medically attended CDI.

The decision is informed by the results of a phase 2b proof-of-concept study that assessed the immunogenicity and safety of the drug in healthy pregnant women and their infants.